Sumitomo Pharma
Sumitomo Pharma Co., Ltd., a prominent player in the global pharmaceutical industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and North America. Founded in 1897, the company has a rich history marked by significant milestones, including advancements in research and development that have positioned it as a leader in innovative healthcare solutions. Specialising in prescription pharmaceuticals, Sumitomo Pharma focuses on areas such as central nervous system disorders, oncology, and regenerative medicine. Its unique approach to drug development, emphasising both quality and efficacy, has led to the creation of several groundbreaking therapies. With a strong market presence and a commitment to improving patient outcomes, Sumitomo Pharma continues to achieve notable recognition within the industry, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Sumitomo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sumitomo Pharma's score of 36 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sumitomo Pharma's reported carbon emissions
In 2023, Sumitomo Pharma reported significant carbon emissions, with total emissions amounting to approximately 356,214,000 kg CO2e. The breakdown of emissions includes Scope 2 emissions at about 26,827,000 kg CO2e and Scope 3 emissions at approximately 356,214,000 kg CO2e. Notably, the company has not disclosed Scope 1 emissions for this year. Looking at previous years, in 2022, Sumitomo Pharma's total emissions were about 54,347,000 kg CO2e, with Scope 1 emissions at approximately 27,829,000 kg CO2e and Scope 2 at about 26,518,000 kg CO2e. The company has shown a commitment to reducing its carbon footprint, setting ambitious targets through the Science Based Targets initiative (SBTi). Specifically, Sumitomo Pharma aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030, using FY2020 as the base year. Additionally, the company plans to cut Scope 3 emissions from purchased goods and services by 25% within the same timeframe. These commitments align with industry standards for climate action, reflecting Sumitomo Pharma's dedication to sustainability and reducing its environmental impact in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 41,805,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - |
| Scope 2 | 38,906,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 35,270,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sumitomo Pharma is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
